Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.